Sequential and Combination Therapy for mCRPC – What Do We Have and How Do We Apply?

索引

00:00 1.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
00:56 2.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
01:01 3.
什麼是mCRPC? 和HRPC有何不同?
01:20 4.
HRPC versus CRPC
02:23 5.
Prostate Cancer Disease Stages
03:15 6.
去勢療法出現抗性的攝護腺癌(CRPC)
03:37 7.
去勢療法出現抗性的攝護腺癌(CRPC)
04:26 8.
Molecular States Framework for AR Activation in Prostate Cancer
04:49 9.
Molecular States Framework for AR Activation in Prostate Cancer
05:34 10.
對於mCRPC,目前有哪些新藥?作用機轉為何?
05:49 11.
Approved New Drugs for mCRPC
06:39 12.
Approved New Drugs for mCRPC
07:02 13.
1966年諾貝爾醫學獎得主
07:21 14.
傳統上賀爾蒙治療的策略
08:22 15.
mCRPC病人賀爾蒙治療的策略
09:07 16.
正常情況下雄性素分泌的比例
09:23 17.
去勢男性雄性素分泌的情形
09:52 18.
Sites of Action by Androgen Biosynthesis Inhibitors
10:34 19.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
10:39 20.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
11:18 21.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
11:22 22.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
12:35 23.
Radium-223 Is a Unique α-Emitter
13:05 24.
[TITLE]
14:14 25.
Principle of Sipuleucel-T
15:40 26.
這些新藥能延長生命嗎? 能減輕痛苦嗎?
15:52 27.
Androgen-Deprivation Therapy雄性素去除療法:Continuous androgen deprivation (pharmaceutical or surgical) should be continued indefinitely regardless of additional therapies(Therapies in Addition to Androgen-Deprivation Therapy)Therapies with demonstrated survival
16:41 28.
Therapies with demonstrated survival benefit and unclear quality-of-life benefit可延長存活期:Sipuleucel-T in asymptomatic or minimally symptomatic p’tCabazitaxel in p’t progressed after docetaxelTherapies with quality-of-life benefit without demonstrated surviv
17:47 29.
Therapies without demonstrated survival or quality-of-life benefit過去臨床試驗證實無效者:BevacizumabEstramustineSunitinibPalliative Care Services緩和醫療Palliative care should be offered to all patients, particularly to those exhibiting symptoms or quality-of-life (QOL)
18:27 30.
New Drugs for Patient with mCRPC after Docetaxel
19:08 31.
New Drugs for Patients with Chemo-naive mCRPC
19:31 32.
這些新藥國內已經上市了嗎? 健保的給付規定?怎麼用呢?
19:41 33.
Approved New Drugs for mCRPC
20:35 34.
Docetaxel : 健保規定
20:53 35.
Abiraterone : 健保規定
21:39 36.
Docetaxel的副作用
22:52 37.
Abiraterone(澤珂)的建議劑量及服藥方式
23:24 38.
Hormone Concentration After Abiraterone Acetate
24:03 39.
Hormone Concentration After Abiraterone Acetate + Dexamethasone
24:33 40.
Abiraterone的副作用
25:12 41.
臨床上如何選擇適合的mCRPC藥物?
25:17 42.
Slide 38
26:13 43.
Index Patient 3: Symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy(有症狀,身體狀況良好,未接受過化療)
26:46 44.
Slide 40
26:47 45.
Index Patient 5: (Symptomatic) mCRPC with good performance status and prior docetaxel chemotherapy(有症狀,身體狀況良好,有接受過化療)
27:30 46.
Slide 42
27:33 47.
Index Patient 2: Asymptomatic or minimally-symptomatic mCRPC without prior docetaxel chemo(沒有症狀,身體狀況良好,沒有接受過化療)
28:20 48.
Proposed Decision Tree forAsymptomatic mCRPC (Clinical factor)
29:16 49.
Slide 45
29:53 50.
Slide 46
30:22 51.
Slide 47
30:35 52.
Common Drug Combination in mCRPC
31:52 53.
結論
33:49 54.
結論

筆記 (0)

未登入或權限不足!

討論

00:00 1.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
00:56 2.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
01:01 3.
什麼是mCRPC? 和HRPC有何不同?
01:20 4.
HRPC versus CRPC
02:23 5.
Prostate Cancer Disease Stages
03:15 6.
去勢療法出現抗性的攝護腺癌(CRPC)
03:37 7.
去勢療法出現抗性的攝護腺癌(CRPC)
04:26 8.
Molecular States Framework for AR Activation in Prostate Cancer
04:49 9.
Molecular States Framework for AR Activation in Prostate Cancer
05:34 10.
對於mCRPC,目前有哪些新藥?作用機轉為何?
05:49 11.
Approved New Drugs for mCRPC
06:39 12.
Approved New Drugs for mCRPC
07:02 13.
1966年諾貝爾醫學獎得主
07:21 14.
傳統上賀爾蒙治療的策略
08:22 15.
mCRPC病人賀爾蒙治療的策略
09:07 16.
正常情況下雄性素分泌的比例
09:23 17.
去勢男性雄性素分泌的情形
09:52 18.
Sites of Action by Androgen Biosynthesis Inhibitors
10:34 19.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
10:39 20.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
11:18 21.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
11:22 22.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
12:35 23.
Radium-223 Is a Unique α-Emitter
13:05 24.
[TITLE]
14:14 25.
Principle of Sipuleucel-T
15:40 26.
這些新藥能延長生命嗎? 能減輕痛苦嗎?
15:52 27.
Androgen-Deprivation Therapy雄性素去除療法:Continuous androgen deprivation (pharmaceutical or surgical) should be continued indefinitely regardless of additional therapies(Therapies in Addition to Androgen-Deprivation Therapy)Therapies with demonstrated survival
16:41 28.
Therapies with demonstrated survival benefit and unclear quality-of-life benefit可延長存活期:Sipuleucel-T in asymptomatic or minimally symptomatic p’tCabazitaxel in p’t progressed after docetaxelTherapies with quality-of-life benefit without demonstrated surviv
17:47 29.
Therapies without demonstrated survival or quality-of-life benefit過去臨床試驗證實無效者:BevacizumabEstramustineSunitinibPalliative Care Services緩和醫療Palliative care should be offered to all patients, particularly to those exhibiting symptoms or quality-of-life (QOL)
18:27 30.
New Drugs for Patient with mCRPC after Docetaxel
19:08 31.
New Drugs for Patients with Chemo-naive mCRPC
19:31 32.
這些新藥國內已經上市了嗎? 健保的給付規定?怎麼用呢?
19:41 33.
Approved New Drugs for mCRPC
20:35 34.
Docetaxel : 健保規定
20:53 35.
Abiraterone : 健保規定
21:39 36.
Docetaxel的副作用
22:52 37.
Abiraterone(澤珂)的建議劑量及服藥方式
23:24 38.
Hormone Concentration After Abiraterone Acetate
24:03 39.
Hormone Concentration After Abiraterone Acetate + Dexamethasone
24:33 40.
Abiraterone的副作用
25:12 41.
臨床上如何選擇適合的mCRPC藥物?
25:17 42.
Slide 38
26:13 43.
Index Patient 3: Symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy(有症狀,身體狀況良好,未接受過化療)
26:46 44.
Slide 40
26:47 45.
Index Patient 5: (Symptomatic) mCRPC with good performance status and prior docetaxel chemotherapy(有症狀,身體狀況良好,有接受過化療)
27:30 46.
Slide 42
27:33 47.
Index Patient 2: Asymptomatic or minimally-symptomatic mCRPC without prior docetaxel chemo(沒有症狀,身體狀況良好,沒有接受過化療)
28:20 48.
Proposed Decision Tree forAsymptomatic mCRPC (Clinical factor)
29:16 49.
Slide 45
29:53 50.
Slide 46
30:22 51.
Slide 47
30:35 52.
Common Drug Combination in mCRPC
31:52 53.
結論
33:49 54.
結論

分享
- Facebook
- Twitter
- LinkedIn
- 嵌入網址
- QR code

索引
筆記
討論
全螢幕

Sequential and Combination Therapy for mCRPC – What Do We Have and How Do We Apply?

長度: 35:51, 瀏覽: 683, 最近修訂: 2017-05-19

00:00 1.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
00:56 2.
Sequential and Combination Therapy for mCRPC : What Do We Have and How Do We Apply?
01:01 3.
什麼是mCRPC? 和HRPC有何不同?
01:20 4.
HRPC versus CRPC
02:23 5.
Prostate Cancer Disease Stages
03:15 6.
去勢療法出現抗性的攝護腺癌(CRPC)
03:37 7.
去勢療法出現抗性的攝護腺癌(CRPC)
04:26 8.
Molecular States Framework for AR Activation in Prostate Cancer
04:49 9.
Molecular States Framework for AR Activation in Prostate Cancer
05:34 10.
對於mCRPC,目前有哪些新藥?作用機轉為何?
05:49 11.
Approved New Drugs for mCRPC
06:39 12.
Approved New Drugs for mCRPC
07:02 13.
1966年諾貝爾醫學獎得主
07:21 14.
傳統上賀爾蒙治療的策略
08:22 15.
mCRPC病人賀爾蒙治療的策略
09:07 16.
正常情況下雄性素分泌的比例
09:23 17.
去勢男性雄性素分泌的情形
09:52 18.
Sites of Action by Androgen Biosynthesis Inhibitors
10:34 19.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
10:39 20.
 Enzalutamide an AR signalling inhibitor: targets multiple steps in the (AR) signaling pathway
11:18 21.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
11:22 22.
Taxane-based Chemotherapy Acts on Microtubules and AR Signaling
12:35 23.
Radium-223 Is a Unique α-Emitter
13:05 24.
[TITLE]
14:14 25.
Principle of Sipuleucel-T
15:40 26.
這些新藥能延長生命嗎? 能減輕痛苦嗎?
15:52 27.
Androgen-Deprivation Therapy雄性素去除療法:Continuous androgen deprivation (pharmaceutical or surgical) should be continued indefinitely regardless of additional therapies(Therapies in Addition to Androgen-Deprivation Therapy)Therapies with demonstrated survival
16:41 28.
Therapies with demonstrated survival benefit and unclear quality-of-life benefit可延長存活期:Sipuleucel-T in asymptomatic or minimally symptomatic p’tCabazitaxel in p’t progressed after docetaxelTherapies with quality-of-life benefit without demonstrated surviv
17:47 29.
Therapies without demonstrated survival or quality-of-life benefit過去臨床試驗證實無效者:BevacizumabEstramustineSunitinibPalliative Care Services緩和醫療Palliative care should be offered to all patients, particularly to those exhibiting symptoms or quality-of-life (QOL)
18:27 30.
New Drugs for Patient with mCRPC after Docetaxel
19:08 31.
New Drugs for Patients with Chemo-naive mCRPC
19:31 32.
這些新藥國內已經上市了嗎? 健保的給付規定?怎麼用呢?
19:41 33.
Approved New Drugs for mCRPC
20:35 34.
Docetaxel : 健保規定
20:53 35.
Abiraterone : 健保規定
21:39 36.
Docetaxel的副作用
22:52 37.
Abiraterone(澤珂)的建議劑量及服藥方式
23:24 38.
Hormone Concentration After Abiraterone Acetate
24:03 39.
Hormone Concentration After Abiraterone Acetate + Dexamethasone
24:33 40.
Abiraterone的副作用
25:12 41.
臨床上如何選擇適合的mCRPC藥物?
25:17 42.
Slide 38
26:13 43.
Index Patient 3: Symptomatic mCRPC with good performance status and no prior docetaxel chemotherapy(有症狀,身體狀況良好,未接受過化療)
26:46 44.
Slide 40
26:47 45.
Index Patient 5: (Symptomatic) mCRPC with good performance status and prior docetaxel chemotherapy(有症狀,身體狀況良好,有接受過化療)
27:30 46.
Slide 42
27:33 47.
Index Patient 2: Asymptomatic or minimally-symptomatic mCRPC without prior docetaxel chemo(沒有症狀,身體狀況良好,沒有接受過化療)
28:20 48.
Proposed Decision Tree forAsymptomatic mCRPC (Clinical factor)
29:16 49.
Slide 45
29:53 50.
Slide 46
30:22 51.
Slide 47
30:35 52.
Common Drug Combination in mCRPC
31:52 53.
結論
33:49 54.
結論

位置

資料夾名稱

2015臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2017-05-19 16:58:15

最近修訂

2017-05-19 19:05:49

長度

35:51